We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Nanosynth Group Plc | NNN | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 0.092 | 01:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 0.092 | 0.092 |
| Industry Sector |
|---|
| TECHNOLOGY HARDWARE & EQUIPMENT |
| Top Posts |
|---|
Posted at 15/4/2023 15:51 by craftyale Interesting, LUCK and HOPE are used far too often by bad investors. Neither are great investment stratergies. |
Posted at 07/4/2023 17:17 by criticalthinker1 I sold out of this long ago. All smoke no fire with the BOD. Jam tomorrow scenario.I kept an interest in reading lse comments ...weighing up the motives of the posters. I think we can leave that there.I agree that the FCA will need to look into this. However, someone will need to approach them re a claim for misleading investors re company social media and RNSs. This person/s will then become known as the claimant and can pursue a PAD. A Pre-Action Disclosure Application, known as a 'PAD' is used when one party, usually a Claimant, isn't certain that they should issue court proceedings and usually needs to see the Defendant's information before deciding what their next move will be. So they should imo request information on company spending (via the FCA or private specialist solicitors) and determine if the company have acted with good faith and proper due diligence (providing a cost benefit analysis) in utilising company money to better the company shareholders. I hope someone does. I think they will find many a contentious activity undertaken by the BODs. Best of luck. If you let them off they will repeat their activities elsewhere. Dan |
Posted at 31/5/2022 09:57 by kingston78 It looks like someone pumping up the stock and then dump it, leaving late investors high and dry with a loss. |
Posted at 23/12/2021 10:21 by newbietrader2000 You have to wonderWhen this announcement was rns the volume was 800mWhere did all this come fromDo you actually think that it was private investors buyingNOIt was brokers who have placing stock and are forward rolling it |
Posted at 16/12/2021 11:35 by average down mug Only scammers here where 2 big investors popeye and poor investor he dumped half saying he wouldn’t sell he crashed it back not me! I’m staying now with my holding for news!!!!!🤡&# |
Posted at 15/12/2021 08:23 by average down mug Interesting 🤡☝A |
Posted at 14/12/2021 17:24 by average down mug Will explode tomorrow can see closer than not to 2p sooo glad popeye out and quietness from poor investor!! Probably sold out now! Both 🛥🤮&# |
Posted at 14/12/2021 15:04 by average down mug 🤡☝A |
Posted at 30/11/2021 11:34 by tomboyb Moderna chief predicts existing vaccines will struggle with OmicronStéphane Bancel foresees ‘material drop’ in current jabs’ effectiveness, sending stocks and oil prices lower Please use the sharing tools found via the share button at the top or side of articles. Copying articles to share with others is a breach of FT.com T&Cs and Copyright Policy. Email licensing@ft.com to buy additional rights. Subscribers may share up to 10 or 20 articles per month using the gift article service. More information can be found at The chief executive of Moderna has predicted that existing vaccines will be much less effective at tackling Omicron than earlier strains of coronavirus and warned it would take months before pharmaceutical companies could manufacture new variant-specific jabs at scale. Stéphane Bancel said the high number of Omicron mutations on the spike protein, which the virus uses to infect human cells, and the rapid spread of the variant in South Africa suggested that the current crop of vaccines may need to be modified next year. “There is no world, I think, where [the effectiveness] is the same level .&thins He added: “I think it’s going to be a material drop. I just don’t know how much because we need to wait for the data. But all the scientists I’ve talked to . . The Moderna chief executive’s comments come as public health experts and politicians have tried to strike a more upbeat tone about existing vaccines’ capacity to confer protection against Omicron. On Monday, Scott Gottlieb, a director of Pfizer and former commissioner of the US Food and Drug Administration, told CNBC: “There’s a reasonable degree of confidence in vaccine circles that [with] at least three doses .&thins Joe Biden, US president, subsequently said Omicron was “a cause for concern, not a cause for panic,” adding that the government’s medical experts “believe that the vaccines will continue to provide a degree of protection against severe disease”. However, Bancel said scientists were worried because 32 of the 50 mutations in the Omicron variant are on the spike protein, which current vaccines focus on to boost the human body’s immune system to combat Covid. Most experts thought such a highly mutated variant would not emerge for another year or two, Bancel added. The Moderna chief’s predictions rattled investors in Europe and Asia on Tuesday, with equities and crude prices dropping. The European Stoxx 600 share index fell around 1.3 per cent with the UK’s FTSE 100, Germany’s Dax and France’s Cac 40 all down by around the same margin. Hong Kong’s Hang Seng index was 2.3 per cent lower. Recommended Covid-19 vaccines Covid-19 vaccine tracker: the global race to vaccinate Mansoor Mohi-uddin, chief economist at the Bank of Singapore, said that while investors were not pricing in a more serious disruption to the global economy from Omicron, it could take weeks for a clearer picture to emerge. “The view is still that it’s going to be a temporary hit, rather like [the Delta variant] turned out to be.” Moderna and Pfizer have become the vaccine suppliers of choice for most of the developed world due to the high effectiveness of their jabs, which are based on messenger RNA (mRNA) technology. In August, Moderna announced that people vaccinated with two doses of its jab “maintained antibodies through six months, including against variants of concern such as the Delta variant”. But studies suggested that the company’s vaccine was less effective at preventing outbreaks of Delta than earlier strains of the virus. Recommended ExplainerCoronavirus pandemic What we know about Omicron variant that has sparked global alarm A Stanford University study of a Delta outbreak at a California prison published last month found that Moderna’s jab was 56.6 per cent effective against infection — substantially lower than the level in studies conducted before the emergence of the variant, the researchers said. Moderna and Pfizer are now working on new vaccines to target the Omicron variant, which the World Health Organization has said poses a “very high risk”. Bancel said data indicating how existing vaccines performed against the Omicron variant, and whether it caused severe disease, should become available within two weeks. But he said it would take several months before an Omicron-specific vaccine could be produced at scale, and suggested there might be a case for giving more potent boosters to the elderly or people with compromised immune systems in the meantime. “[Moderna] and Pfizer cannot get a billion doses next week. The maths doesn’t work. But could we get the billion doses out by the summer? Sure,” said Bancel, who predicted Moderna could make a total of 2bn-3bn doses in 2022. But he said it would be risky to shift Moderna’s entire production capacity to an Omicron-targeted jab at a time when other variants were still in circulation. Bancel also hit out at critics who have accused vaccine makers of not doing enough to support rollouts in developing countries such as South Africa, where only a quarter of the population is fully inoculated, according to Johns Hopkins University. “This was mostly a policy decision by the rich countries. In the US, we were told we had no choice but to give 60 per cent of our output to the US government. That was not a Moderna decision, that was a US government decision,” he said. Bancel also said there was a surplus of jabs earmarked for Africa and that 70m Moderna vaccines were sitting in warehouses because Covax, an international body tasked with supplying low-income nations, or individual governments had not taken delivery of them. “We are running out of space,” he said. “It’s because either they don’t have customs documents, or they don’t have fridge space, or because the ability to get doses in arms is a challenge.” Additional reporting by Hudson Lockett in Hong Kong |
Posted at 02/9/2021 20:38 by bmwman3 Your contributions appear on this board, when the share price was waning following an abrupt rise. You seem to derive pleasure from goading at investors because the share price is temporarily declining. In doing so, you have created a poor impression of yourself, and investors on this board will no doubt judge you as a highly immature individual. I suspect that you have contributed here on other occasions under a different name, and this is your way of finding some "excitement" in an otherwise dull and unremarkable existence? |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
